TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20937130
Drug: NGX-4010 (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX-4010 (8% capsaicin patch) in patients with PHN for at least 6 months
Study: 20937130
Drug: 0.04% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04% capsaicin control patch in patients with PHN for at least 6 months
Study: 20937130
Drug: NGX-4010 (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX-4010 (8% capsaicin patch) at week 12 in patients with PHN for at least 6 months
Study: 20937130
Drug: 0.04% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04% capsaicin control patch at week 12 in patients with PHN for at least 6 months
Study: 9932855
Drug: Cisapride 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 0.3 mg/kg four times a day for 8 weeks
Study: 1969196
Drug: Local analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local analgesics (lignocaine)
Study: 1969196
Drug: Topical analgesic
Normalized name: Tricylate 2%-10% Topical Analgesic Cream
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical analgesic cream (EMLA)
Study: 7451917
Drug: Single extraamniotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single extraamniotic dose of F2-alpha prostaglandin gel
Study: 31985294
Drug: CinnoRA® (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CinnoRA® (40 mg subcutaneous injection)
Study: 31985294
Drug: Humira® (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humira® (40 mg subcutaneous injection)
Study: 26036466
Drug: S-1 daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 daily administration (Arm A)
Study: 26036466
Drug: S-1 alternate-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 alternate-day administration (Arm B)
Study: 24184429
Drug: sertraline at
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline at standard dosing + CBT
Study: 24184429
Drug: sertraline titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline titrated slowly + CBT
Study: 24184429
Drug: pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: pill placebo + CBT
Study: 8852869
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium lactate infusions
Study: 2049259
Drug: Cifenline alone
Normalized name: cifenline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cifenline alone (160 mg)
Study: 6363798
Drug: Indomethacin, 25
Normalized name: Indomethacin, 25 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 25 mg four times daily for 3 weeks
Study: 31512500
Drug: Devimistat (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Devimistat (2000 mg/m2) in combination with high dose cytarabine and mitoxantrone
Study: 31512500
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cytarabine and mitoxantrone alone
Study: 11742907
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution (4.5%) inhalation
Study: 11742907
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution (0.9%) inhalation
Study: 7973107
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol (5 mg) given 4 times daily for 24 hours on 2 consecutive days
Study: 7973107
Drug: Saline given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline given 4 times daily for 24 hours on 2 consecutive days
Study: 2659302
Drug: Sucrose-containing snacks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose-containing snacks (7% of total daily calories)
Study: 2659302
Drug: Aspartame-sweetened snacks
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame-sweetened snacks (1% of total daily calories)
Study: 30980248
Drug: Non-daily smokers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-daily smokers
Study: 29354957
Drug: Fire needle
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire needle plus chemotherapy
Study: 18271771
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy with 0.2% minocycline
Study: 18271771
Drug: Placebo aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aqueous solution mouthwash
Study: 12430110
Drug: Single stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single stimulation group (30 mL local anesthetic injected after locating 1 motor response)
Study: 12430110
Drug: Multistimulation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multistimulation group (10 mL local anesthetic injected on each of 3 motor responses)
Study: 10087113
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of mangafodipir trisodium (Mn‐DPDP) at a dosage of 5 micromol/kg.
Study: 7552592
Drug: Enteral allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral allopurinol (20 mg/ml) for seven daily doses
Study: 7552592
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent dose) for seven daily doses
Study: 7552592
Drug: Enteral allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral allopurinol (20 mg/ml)
Study: 2210808
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (200 mmol sodium/day) as a supplement to the low salt diet for a third week
Study: 6933738
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg cyproterone acetate at weekly intervals
Study: 6933738
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oestradiol‐17 beta‐undecylate every month
Study: 6151553
Drug: Prizidilol hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol hydrochloride (200‐300 mg b.i.d.)
Study: 31348732
Drug: Language-specific attention
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Language-specific attention treatment (L-SAT)
Study: 26814620
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) 200U subcutaneous injection
Study: 22790464
Drug: Hepatitis C
Normalized name: hepatitis C virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis C antiviral therapy offered to patients in opioid agonist treatment
Study: 20962312
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil beverage (1.5 g per day for 12 weeks)
Study: 16225928
Drug: Early retreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early retreatment with verteporfin therapy every 2 months (group A)
Study: 16225928
Drug: Standard verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard verteporfin therapy every 3 months (group B)
Study: 16225928
Drug: Early retreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early retreatment with verteporfin therapy (group A)
Study: 16225928
Drug: Standard verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard verteporfin therapy (group B)
Study: 29561188
Drug: Sitagliptin-Metformin (SITA-MET)
Normalized name: linagliptin / metformin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin-Metformin (SITA-MET)
Study: 27218868
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 mg/d for 1 week and then 30 mg/d for 12 weeks)
Study: 15058375
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment alone (control group)
Study: 10640160
Drug: Norplant implant
Normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norplant implant
Study: 10640160
Drug: Domestic implant
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic implant
Study: 7589771
Drug: Alpha-glucosidase inhibitor
Normalized name: Alpha-glucosidase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-glucosidase inhibitor (0.6 mg/day) combined with sulphonylurea (glibenclamide or tolbutamide) for 4 weeks
Study: 7015536
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of penbutolol (40 mg) and furosemide (20 mg)
Study: 7015536
Drug: Reference formulations:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulations: Penbutolol capsules (40 mg) and furosemide (20 mg) tablets
Study: 11929440
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy programme for adult survivors of child abuse and neglect
Study: 9617508
Drug: Ropinirole (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (mean daily dose 8.7 mg in early therapy; 8.2 mg in adjunct therapy)
Study: 2656070
Drug: Prostacyclin (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (PGI2) during ANG II infusion
Study: 8848911
Drug: Balanced analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced analgesia (5 ml of 2% lidocaine gel on the clips and 200 mg of ketoprofen i.v.)
Study: 8848911
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml of placebo gel on the clips and placebo i.v.)
Study: 8848911
Drug: Lidocaine group
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine group (5 ml of 2% lidocaine gel on the clips and placebo i.v.)
Study: 8504578
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (bolus doses of 5 + 5 mmol followed by infusion of 0.04 mmol/min)
Study: 8504578
Drug: Verapamil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (5 + 5 mg followed by 0.1 mg/min)
Study: 23234601
Drug: pegIFNα‐2a continuing
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegIFNα‐2a continuing monotherapy (group A, n = 51)
Study: 23234601
Drug: Adefovir (ADV)
DrugBank: Adefovir (DB13868)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir (ADV) add‐on therapy (group B, n = 34)
Study: 15261701
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor agonist bromocriptine 3.125 mg
Study: 10680473
Drug: r-HuEPO (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-HuEPO (300 IU/kg on day four before surgery and 150 IU/kg daily for the following seven days)
Study: 8975318
Drug: Resting 99mTc-MIBI
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resting 99mTc-MIBI SPECT after nitroglycerine (NTG) administration
Study: 1757606
Drug: 0.05% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% betamethasone dipropionate ointment
Study: 28819778
Drug: Jumihaidokuto (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jumihaidokuto (6 g daily)
Study: 28819778
Drug: Control (antihistamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antihistamines only)
Study: 25833401
Drug: Subcutaneous PEG‐IFN‐β1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous PEG‐IFN‐β1a
Study: 25833401
Drug: Conventional IFN‐β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional IFN‐β drugs
Study: 17127381
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine (35 microg/h)
Study: 17127381
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine (60 mg/day)
Study: 9385692
Drug: Routine epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine epidural corticosteroid injections
Study: 9385692
Drug: Rest and
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest and a nonsteroidal antiinflammatory drug
Study: 4934047
Drug: Levorphanol 2
Normalized name: levorphanol 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levorphanol 2 mg
Study: 4934047
Drug: Pentazocine 20
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentazocine 20 mg
Study: 4934047
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg and Cyclizine 50 mg combination
Study: 31519277
Drug: Dengzhan Shengmai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengzhan Shengmai (DZSM) capsules, 0.36 g, twice daily for 12 months
Study: 28650791
Drug: Papain gel
Normalized name: Papain
DrugBank: Papain (DB11193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papain gel after acid etching for 60 seconds
Study: 28650791
Drug: Bromelain gel
DrugBank: Bromelains (DB13281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromelain gel after acid etching for 60 seconds
Study: 24621936
Drug: Standard CHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CHF therapy (Control)
Study: 21644059
Drug: MK‐3134 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐3134 25 mg
Study: 21644059
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MK‐3134 and Donepezil
Study: 18552277
Drug: Istradefylline (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istradefylline (40 mg daily for 14 days)
Study: 18552277
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg single dose)
Study: 11139103
Drug: Fentanyl (8.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (8.1 ng/mL)
Study: 11139103
Drug: Sufentanil (0.68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.68 ng/mL)
Study: 8472829
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg budesonide
Study: 30153096
Drug: Hydroxycarbamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxycarbamide plus aspirin
Study: 24704290
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml aspiration
Study: 24704290
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml aspiration
Study: 24704290
Drug: 0 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 ml aspiration (no aspiration)
Study: 16036198
Drug: Step-up ovulation
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up ovulation induction treatment with recombinant follicle-stimulating hormone followed by intrauterine insemination for three cycles
Study: 9926183
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg i.v. before propofol (2 mg/kg) induction (Group A)
Study: 9926183
Drug: Lidocaine 40
Normalized name: lidocaine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 40 mg (Group D)
Study: 340332
Drug: Cimetidine plus
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine plus antacid
Study: 340332
Drug: Cimetidine plus
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine plus dummy antacid
Study: 340332
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet plus antacid
Study: 25461822
Drug: Motor Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor Learning (ML) alone
Study: 25461822
Drug: Robotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotics plus Motor Learning (ML)
Study: 25461822
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Stimulation (FES) plus Motor Learning (ML)
Study: 23365053
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine 25 mg
Study: 23365053
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam 2 mg
Study: 19584603
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity (PA) during treatment
Study: 15034827
Drug: New cell-cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cell-cultured smallpox vaccine
Study: 15034827
Drug: Live vaccinia
Normalized name: Smallpox (Vaccinia) Vaccine, Live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live vaccinia virus vaccine
Study: 11685164
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 70 U/kg
Study: 11685164
Drug: Both unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both unfractionated heparin and dalteparin
Study: 9922821
Drug: Customary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customary treatment
Study: 7998416
Drug: B subunit-whole
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: B subunit-whole cell cholera vaccine (B-WC), 2 or 3 doses
Study: 7998416
Drug: B subunit-whole
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: B subunit-whole cell cholera vaccine (B-WC), 2 doses
Study: 7998416
Drug: New B
Normalized name: Little Remedies New Baby Essentials Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: New B subunit-whole cell cholera vaccine (recombinant B subunit)
Study: 1947729
Drug: High-dose corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroids (HDC)
Study: 25609264
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs enriched intravenous fat emulsion (IVFE)
Study: 23875551
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral group therapy (4 sessions)
Study: 18379396
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg for 4 weeks, then maintained or titrated to 5 or 20 mg at weeks 4 and 8
Study: 10574413
Drug: Irbesartan monotherapy
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan monotherapy started at 75 mg and titrated to 300 mg
Study: 8921578
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg initially, 1 mg every four hours for 24 hours)
Study: 8921578
Drug: Somatostatin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (250 micrograms bolus and continuous infusion of 250 micrograms/h for 24 hours)
Study: 2060544
Drug: Amitriptyline (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (37.5 mg)
Study: 30166329
Drug: eBEACOPP (escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: eBEACOPP (escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone)
Study: 18046975
Drug: Zofenopril 30-60
Normalized name: zofenopril 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 30-60 mg once daily
Study: 11094308
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) alpha‐2b at a dose of 20 MU/m2/day, 5 days per week for one month, followed by 10 MU/m2 TIW, up to one complete year of therapy
Study: 3011048
Drug: Intravenous trimazosin
Normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trimazosin (100 mg)
Study: 3011048
Drug: Oral trimazosin
Normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimazosin (200 mg)
Study: 27733571
Drug: SC IFN‐β‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC IFN‐β‐1a 44 μg
Study: 24959193
Drug: Shen-Zhi-Ling oral
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shen-Zhi-Ling oral liquid (SZL)
Study: 22399518
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg daily for 6 weeks)
Study: 20726258
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose booster of HepB
Study: 20726258
Drug: 3 dose
Normalized name: Hep A, ped/adol, 3 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 dose booster of HepB
Study: 20726258
Drug: 4 different
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 different types of HepB (5 microg HepB-Y, 10 microg HepB-Y, 10 microg HepB-CHO, 10 microg HepB-HY) after 3 doses revaccination
Study: 17681993
Drug: Active treatments
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatments for smoking cessation (specific treatments not detailed)
Study: 17849193
Drug: New tests
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tests of the same four predictor domains administered to N=500 late kindergartners through third graders
Study: 8542861
Drug: nalbuphine mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine mixed with lignocaine (2 mg mL‐1)
Study: 8542861
Drug: diluted nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: diluted nalbuphine (2 mg mL‐1)
Study: 1930343
Drug: Midazolam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (7.5 mg)
Study: 6885176
Drug: Erythromycin lactobionate
Normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin lactobionate (1 g in 0.9% NaCl) infused in 120 ml